AMRX Q4 2022 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q4 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$610M+13.6% YoY

Gross Profit

$215M35.3% margin

Operating Income

$36M5.9% margin

Net Income

-$4M-0.7% margin

EPS (Diluted)

$-0.04

QoQ Revenue Growth

+11.8%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$35M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$3.8B

Total Liabilities

$3.6B

Stockholders' Equity

$298M

Cash & Equivalents

$26M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$610M	$537M	+13.6%
Gross Profit	$215M	$166M	+29.4%
Operating Income	$36M	$11M	+222.4%
Net Income	-$4M	-$6M	+32.1%

Revenue Segments

Generics Segment

$399M65%

Av K A R E Segment

$108M18%

Amneal Specialty Pharma Segment

$103M17%